1Buy.AI | $3,900,000 | (Feb 3, 2026)
PranaX | $17,000,000 | (Feb 3, 2026)
DexMat | $5,000,000 | (Feb 3, 2026)
Predicta Biosciences
United States
- Cambridge, Massachusetts
- 17/07/2024
- Seed
- $5,200,000
Predicta Biosciences is a precision oncology company integrating cutting edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Predicta's diagnostic product portfolio removes the burden of bone-marrow biopsies, through small blood-based samples, and enables best-in-class treatment decision-making for immunotherapies. Utilizing the data from the diagnostic platform, Predicta has an in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development.
- Industry Biotechnology Research
- Website https://www.predictabiosciences.com/
- LinkedIn https://www.linkedin.com/company/predicta-biosciences/
Related People
Kate (Gallagher) CavesFounder
United States -
Greater Boston
Executive Leader with Business Development, Corporate Development, Marketing and deep technical background in Therapeutic Development and Diagnostic tools. Passionate about the intersection of Biology, Healthcare, and AI.
Prenosis | $20,000,000 | (Feb 3, 2026)
CloudForge AI | $3,950,000 | (Feb 3, 2026)
Linq | $20,000,000 | (Feb 3, 2026)
Breezy | $10,000,000 | (Feb 3, 2026)
Poetiq | $45,800,000 | (Feb 3, 2026)
JJG Machining Group | $30,000,000 | (Feb 3, 2026)
Principle | $2,000,000 | (Feb 3, 2026)
BizTrip AI | $1,500,000 | (Feb 3, 2026)
Co-reactive | $7,754,157 | (Jan 30, 2026)